JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us
このページは機械翻訳されています。他のページは英語で表示される場合があります。 View in English

AKTとEZH2阻害剤は,インヴォルションのメカニズムをハイジャックすることによってTNBCを殺す.

  • 0Division of Genetics, Brigham and Women's Hospital, Boston, MA, USA.
Nature +

|

2024年10月9日

|

2024年10月9日

PubMedで要約を見る

まとめ

この要約は機械生成です。

AKTとEZH2阻害剤を用いた新しい組み合わせ治療は,トリプルネガティブ乳がん (TNBC) の治療に有望である. このアプローチは ガン細胞を分化して除去することで 攻撃的な腫瘍を効果的に減少させます

科学分野

  • 腫瘍学
  • 分子生物学
  • エピジェネティクス

背景

  • トリプルネガティブ乳がん (TNBC) は,高い再発率と限られた治療選択肢を持つ攻撃的なサブタイプです.
  • 現在の化学療法と免疫療法は 短期的な効果をもたらし 新しい治療戦略の必要性を強調しています
  • PI3K経路はTNBCで頻繁に変化しますが,このサブタイプの阻害剤に対する反応は十分に理解されていません.

研究 の 目的

  • トリプルネガティブ乳がん (TNBC) の治療のための新しい組み合わせを調査する.
  • TNBCモデルにおけるAKT阻害剤とEZH2抑制剤の相乗効果を調査する.
  • この併用療法によって誘発される腫瘍の逆行の根本的なメカニズムを解明する.

主な方法

  • 結合されたAKTとEZH2阻害剤の有効性をテストするために,in vivo TNBCモデルを使用した.
  • 抑制剤によって誘発される細胞状態の変化 (差別化) を調査した.
  • 予測感度分類器を開発するために機械学習のアプローチを採用しました.

主要な成果

  • AKTとEZH2阻害剤は,TNBCモデルで強固な腫瘍の回帰を相乗的に促進する.
  • 組み合わせ治療は TNBC 細胞を 光状の分化状態に駆り立てます これは TNBC 細胞の除去に不可欠です
  • 乳腺のインヴォルション経路をハイジャックし 癌細胞の死滅を誘発します
  • この組み合わせ療法に対する患者の感受性を予測するために,機械学習分類器が開発されました.

結論

  • AKTとEZH2阻害剤の組み合わせは,トリプルネガティブ乳がんの治療戦略として有望である.
  • このアプローチはTNBCを効果的に標的にし,分化を引き起こし,発達の細胞死経路を利用します.
  • エピジェネティック酵素と 発達経路の役割を理解することで 侵襲的な癌の治療に 新たな道が開かれます

関連する概念動画

Targeted Cancer Therapies 02:57

7.5K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity 02:34

4.7K

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

The Intrinsic Apoptotic Pathway 01:31

6.4K

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

Mitogens and the Cell Cycle 02:38

6.4K

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal 01:22

2.2K

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.

Cancer Cell Migration through Invadopodia 01:35

2.3K

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...